Zealand Pharma Past Earnings Performance
Past criteria checks 0/6
Zealand Pharma's earnings have been declining at an average annual rate of -41.9%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 26.7% per year.
Key information
-41.9%
Earnings growth rate
-36.1%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 26.7% |
Return on equity | -305.2% |
Net Margin | -403.0% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zealand Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 278 | -1,118 | 611 | 619 |
30 Jun 22 | 288 | -1,108 | 624 | 613 |
31 Mar 22 | 302 | -957 | 590 | 606 |
31 Dec 21 | 293 | -1,018 | 636 | 588 |
30 Sep 21 | 158 | -925 | 416 | 595 |
30 Jun 21 | 161 | -1,012 | 480 | 595 |
31 Mar 21 | 347 | -909 | 575 | 574 |
31 Dec 20 | 353 | -847 | 468 | 604 |
30 Sep 20 | 301 | -660 | 300 | 612 |
30 Jun 20 | 255 | -545 | 178 | 596 |
31 Mar 20 | 54 | -624 | 79 | 605 |
31 Dec 19 | 41 | -572 | 68 | 561 |
30 Sep 19 | 43 | -508 | 68 | 522 |
30 Jun 19 | 33 | 524 | 62 | 486 |
31 Mar 19 | 28 | 551 | 50 | 471 |
31 Dec 18 | 38 | 581 | 44 | 438 |
30 Sep 18 | 35 | 601 | 49 | 394 |
30 Jun 18 | 74 | -361 | 47 | 375 |
31 Mar 18 | 68 | -346 | 52 | 347 |
31 Dec 17 | 136 | -274 | 47 | 324 |
30 Sep 17 | 306 | -112 | 58 | 293 |
30 Jun 17 | 307 | -100 | 55 | 274 |
31 Mar 17 | 306 | -102 | 61 | 259 |
31 Dec 16 | 231 | -157 | 59 | 262 |
30 Sep 16 | 221 | -138 | 51 | 243 |
30 Jun 16 | 189 | -158 | 55 | 237 |
31 Mar 16 | 188 | -139 | 48 | 224 |
31 Dec 15 | 188 | -114 | 48 | 212 |
Quality Earnings: 22ZA is currently unprofitable.
Growing Profit Margin: 22ZA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 22ZA is unprofitable, and losses have increased over the past 5 years at a rate of 41.9% per year.
Accelerating Growth: Unable to compare 22ZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 22ZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 22ZA has a negative Return on Equity (-305.23%), as it is currently unprofitable.